XORTX Therapeutics (CSE:XRX) recently announced the appointment of Dave Matthews as CFO, replacing John Meekison, who acted as interim CFO for XORTX since the company’s founding. Mr. Meekison will remain with XORTX to assist with the transition.Read More
Ortho Regenerative Technologies (CSE:ORTH) has received a notice of allowance from the European Patent Office that when issued, will provide intellectual property protection for the composition of matter of its Ortho-R implants for the biologic repair of tissue.Read More
Ortho Regenerative Technologies (CSE:ORTH) announced that a peer-reviewed article detailing the tissue regeneration properties of its implants was published in the current issue of Journal of Tissue Engineering and Regenerative Medicine.Read More
Ortho Regenerative Technologies (CSE:ORTH.CN) announced that a peer-reviewed article entitled, "Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine Models," has been published in the current issue of Regenerative Medicine and Therapeutics.Read More
Ortho Regenerative Technologies (CSE:ORTH) appointed Dr. Jacques Toueg to its scientific advisory board (SAB).Read More
A peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that Ortho Regenerative Technologies’ (CSE:ORTH) Ortho-R hybrid implants release more growth factors and reside longer in the body than platelet rich plasma (PRP) alone.Read More
Tetra BioPharma (OTCQB:TBPMF; CSE:TBP) appointed Bernard Fortier to the position of CEO, effective July 24.Read More
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.Read More
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) and the New Brunswick Health Research Foundation are investing $500,000 each over five years to establish a health research chair in cannabis at the University of New Brunswick.Read More
Tetra Bio-Pharma (CSE:TBP; OTCQB:TBPMF) and subsidiary, PhytoPain Pharma, have submitted a report on the safety and pharmacokinetics of its PPP001 smokeable cannabis product to Health Canada.Read More
IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia and cancer chemotherapy-related pain.Read More
IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.Read More
M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project.
The third study, conducted in India, found that C-103 was over 97% effective in eliminating the GI adverse events associated with orlistat.Read More
Pivotal Therapeutics (CSE:PVO; OTC PINK:PVTTF) currently is unable to repay $7.7-million of convertible notes, which came due March 4, 2016, and at least one noteholder has advised the company that it intends to petition Pivotal into bankruptcy.
Noteholders also have advised Pivotal that they are not prepared to advance additional funds to the company.Read More